<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Immunotherapy on FinanClub</title>
    <link>https://finan.club/tags/immunotherapy/</link>
    <description>Recent content in Immunotherapy on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Tue, 27 Feb 2024 09:04:54 +0000</lastBuildDate><atom:link href="https://finan.club/tags/immunotherapy/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>IBRX</title>
      <link>https://finan.club/us/ibrx/</link>
      <pubDate>Tue, 27 Feb 2024 09:04:54 +0000</pubDate>
      
      <guid>https://finan.club/us/ibrx/</guid>
      <description>score:142
Chances: Completion of enrollment for safety portions of a clinical trial is a positive indicator of progress for the company Findings from Patient-Reported Outcomes (PROs) and positive interim results from the QUILT 3.032 study showcase the potential of ImmunityBio’s therapies Acceptance for review of the Biologics License Application (BLA) for N-803 by the FDA demonstrates a significant milestone for the company Risks: The success of the clinical trials and the FDA review are crucial for the company’s future prospects, and any setbacks in these processes could impact the stock performance Competitive landscape and regulatory environment for immunotherapy companies may pose challenges Score:142 chances characters count - risks characters count = 142</description>
    </item>
    
  </channel>
</rss>
